Jehonathan H. Pinthus, MD, PhD, FRCSC, explains factors that influence a bladder cancer patient’s risk of thromboembolic complications and prevention methods. His discussion includes the optimal timing of venous thromboembolism (VTE) prophylaxis after radical cystectomy, how cisplatin-based neoadjuvant chemotherapy effects thromboembolic events, and his opinion on current guidelines.Read More
Jehonathan H. Pinthus, MD, PhD, FRCSC
Hamilton, ON, Canada
Jehonathan Pinthus MD, PhD is an Associate Professor in the Department of Surgery Division of Urology McMaster University. He is a surgical oncologist-Urologist who completed his MD at the Hebrew University in Jerusalem Israel and his Urology training at the Sheba Medical Centre Tel Aviv University Israel. He then completed 2.5 years of SUO- accredited fellowship in Uro-Oncology in the University of Toronto. Dr. Pinthus earned his PhD at the Weizmann Institute of Science working on gene immunotherapy of prostate cancer. He is heading a basic and translational research laboratory at McMaster University and his research interests relates to the patients individual host factors and metabolism that affects prostate cancer growth and response to therapy. Dr. Pinthus published more than 80 peer reviewed papers, several book chapters and is a member of the editorial board of European Urology and Prostate Cancer and Prostatic Disease journals. Dr. Pinthus is the principle investigator on many distinguished research grants the most recent one is a $3.5 M Movember-Prostate Cancer Canada grant titled " Role of androgen deprivation therapy in cardiovascular disease - a longitudinal prostate cancer study (RADICAL PC)" to prospectively address the potential link between prostate cancer in general and androgen deprivation therapy (ADT) in particular and an increased risk of cardiovascular disease.
Articles by Jehonathan H. Pinthus, MD, PhD, FRCSC
Dr. Jehonathan Pinthus presented “Treatment of Invasive Bladder Cancer in the Elderly and...Read More